SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are sharply divided over a tokenized crypto asset claiming to represent SpaceX shares, with many warning it is a deceptive scheme unrelated to the company. While the community remains highly skeptical of these digital tokens, genuine excitement is building around the anticipated public listing of the space giant, sparking intense debate over valuations, sector competition, and the risks of falling for speculative pre-IPO hype.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is attracting significant community attention due to its focus on decentralized infrastructure, including sovereign cloud initiatives and AI-integrated applications that aim to bypass traditional tech giants. While some investors remain cautious about long-term price performance and market volatility, others are actively accumulating based on the project's ongoing technical developments and potential for real-world utility.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as the community debates its long-term viability amid stagnant price action and anticipation surrounding the CLARITY Act's impact on crypto payment regulation. While some investors are aggressively accumulating tokens on the expectation of institutional adoption, others express deep frustration over the lack of transparency, declining market value, and the project's perceived inability to move in lockstep with the broader market.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. is attracting significant community attention due to its unique integration of critical mineral processing and magnet manufacturing, which investors view as a strategic hedge against supply chain volatility. Discussions are centered on the stock's extremely low float and its potential for high-volatility price action, with many users debating whether its recent momentum is driven by fundamental breakthroughs in domestic supply chain positioning or speculative trading patterns common in new listings.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO Network is seeing heightened community frustration and debate as investors react to recurring price volatility and perceived lack of follow-through on past project milestones. While some participants are actively accumulating tokens in anticipation of future DePin sector momentum and broader altcoin growth, many others remain vocal about what they characterize as a repetitive cycle of speculative pumps and sell-offs.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

FARTCOIN is capturing significant community attention as traders debate its potential for a rebound and speculate on its relationship with other meme coins like $UPDOG. While some investors are actively buying the dip, discussion remains polarized between those anticipating a major breakout and others who are skeptical of the token's long-term sustainability.

Qorvo, Inc. provides semiconductor solutions for RF and power. The firm combines product and technology leadership, systems-level expertise, and global manufacturing scale to quickly solve its customers' most complex technical challenges. Qorvo serves diverse high-growth segments of large global markets, including consumer electronics, smart home/IoT, automotive, EVs, battery-powered appliances, network infrastructure, healthcare, and aerospace/defense. It operates through the following segments: High Performance Analog (HPA), Connectivity and Sensors Group (CSG), and Advanced Cellular Group (ACG). The HPA segment supplies RF and power management solutions for infrastructure, defense and aerospace, automotive power, and other markets. The CSG segment supplies connectivity and sensor components and systems featuring multiple technologies such as UWB, Matter, Bluetooth Low Energy, Zigbee, Thread, Wi-Fi, cellular IoT and MEMS-/BAW-based sensors. The ACG segment supplies cellular RF solutions for smartphones, wearables, laptops, tablets, and various other devices. The company was formed following the merger of RF Micro Devices, founded in 2015, and TriQuint Semiconductor, incorporated in 1981. It is headquartered in Greensboro, NC.

Qorvo Inc

Qorvo is trending following a series of analyst downgrades that highlight concerns over handset market saturation and the company's heavy reliance on smartphone demand. Market participants are actively debating the long-term impact of its pending merger with Skyworks and the potential for structural headwinds in the RF semiconductor sector.

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics is currently in focus as investors await clarity following a recent Complete Response Letter for its lead phosphate binder candidate, with the company actively coordinating with the FDA to resolve manufacturing deficiencies. Community discussion remains heavily centered on the upcoming July 14th virtual conference participation and the potential for a rapid regulatory re-submission path that could de-risk the investment thesis ahead of a commercial launch.

Tidal Trust II - YieldMax Ultra Option Income Strategy ETF

YieldMax Ultra Option Income Strategy ETF

ULTY is trending as investors debate the potential long-term implications of a 1-for-10 reverse stock split alongside ongoing concerns about NAV erosion. Community discussions are heavily split between those viewing the distribution history as a path to eventual cost-basis recovery and skeptics who maintain that the underlying strategy remains structurally flawed.

Virtuals Protocol is a launchpad platform launched in 2024 that enables users to create, tokenize, and monetize AI agents for gaming, entertainment, and virtual environments without requiring technical expertise. Initially built on Ethereum's Base Layer 2 network, the protocol has expanded to Ethereum mainnet, Solana, and Ronin as of 2025. VIRTUAL serves as the base liquidity pair and transactional currency for all AI agent interactions across the ecosystem.  The protocol operates through a bonding curve system where new AI agents are created with a 100 VIRTUAL fee. Users can buy and sell agent tokens until the agent reaches 42,000 VIRTUAL, at which point it graduates to a permanent liquidity pool paired with VIRTUAL. AI agents are multimodal, capable of text, speech, and 3D animation, and can manage on-chain wallets autonomously. Notable examples include Luna, an AI girl band vocalist with over 500,000 TikTok followers. The GAME framework powers agent functionality, enabling them to process inputs, generate responses, and remember past interactions.  Virtuals Protocol was founded by Jansen Teng and Weekee Tiew, evolving from PathDAO, a gaming guild established in 2021 that pivoted to AI agents in January 2024. The team raised $16 million in seed funding led by DeFiance Capital and Beam. In 2025, major partnerships were announced with Animoca Brands and a collaboration with Zyfai and BasisOS to launch an Agentic Fund of Funds.  Users can stake VIRTUAL tokens for veVIRTUAL to participate in DAO governance and may receive airdrops of agent tokens. When users interact with agents, they pay fees in VIRTUAL that generate protocol revenue. This revenue funds periodic buybacks and burns of the VIRTUAL token, reducing its total supply as a value-accrual mechanism for holders.

Virtual Protocol

Virtual Protocol is currently a major focus for the AI agent sector, with the community closely tracking potential catalysts like Coinbase listings and broader integration within the Agentic AI narrative. While some traders are expressing frustration over price volatility, the conversation remains heavily centered on long-term accumulation and optimistic projections for the token's role in the expanding AI agent economy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Global ETFs Back in the Spotlight on Macroeconomic Tailwinds

Easing geopolitical tensions, a softer dollar and improving risk appetite are reviving interest in global equity ETFs.

<ul class="summary-bullets"><li>Jefferies analyst Michael Leuchten maintained a ‘Buy’ rating and $243 price target on AstraZeneca following the committee vote on camizestrant.</li><li>This suggests that the FDA is now unlikely to approve the drug in this setting, the analyst noted.</li><li>However, "this should come as no surprise," the analyst said.</li></ul>Shares of AstraZeneca (AZN) closed up 1% on Thursday after Wall Street dismissed the negative vote on the company’s breast cancer drug as unsurprising.The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) voted 6-3 against a favorable benefit-risk profile for AstraZeneca’s camizestrant in combination with other drugs for the treatment of certain patients with advanced breast cancer, AstraZeneca said.The FDA accepted AstraZeneca's application for camizestrant in July 2025 based on the results of a late-stage trial, which showed a 56% reduction in the risk of disease progression or death with the camizestrant combination versus standard-of-care treatment.The FDA does not have to abide by the committee’s opinion, but takes its advice into consideration, the company noted. AstraZeneca’s application continues to be under the agency’s review. &nbsp;Regulatory applications for camizestrant in this setting are also under review in the EU, Japan, and several other countries, AstraZeneca noted.<h2 class="st-heading-2">Analyst Chimes In</h2>Jefferies analyst Michael Leuchten maintained a ‘Buy’ rating and $243 price target on AstraZeneca following the committee vote on camizestrant. This suggests that the FDA is now unlikely to approve the drug in this setting, the analyst noted, while adding that "this should come as no surprise" after the publication of the prior briefing documents.The analyst noted that the trial in question is not part of the firm's ‘Buy’ thesis, and the trial accounts for "only a small part of the $80B 2030 sales target." The company reported total revenue of $58.74 billion in 2025.Jefferies concluded that any weakness following this news "presents a buying opportunity."<h2 class="st-heading-2">How Did AZN Retail Traders React?</h2>On Stocktwits, retail sentiment around AZN rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/AZN">AZN stock</a> has gained 29% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-rallies-after-hours-on-q1-beat-while-investors-pile-into-r2-story/cZBMZyIReI9">RIVN Rallies After-Hours On Q1 Beat While Investors Pile Into R2 Story</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AZN Stock Rise As Wall Street Dismisses FDA Committee’s Rejection Of Breast Cancer Drug 

FDA’s Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote on the benefit-risk profile of AstraZeneca’s camizestrant in combination with other drugs. 

Equity

<ul class="summary-bullets"><li>The oil supermajor said that its reported profit for the quarter was $3.8 billion, compared with a loss of $3.4 billion for the fourth quarter of 2025.</li><li>The quarter marks the first set of results under new CEO Meg O'Neill, who is the company’s fourth leader in six years.</li><li>BP said it expects lower upstream production in Q2 due to seasonal maintenance and disruptions in the Middle East.</li></ul>British oil major BP Plc (BP) saw its shares rise by over 3.5% in Tuesday’s premarket trade after the company reported that its first-quarter (Q1) profit more than doubled amid a surge in global oil and gas prices. &nbsp;BP said its underlying replacement-cost profit, which it uses as a proxy for net profit, came in at $3.2 billion for the quarter, compared with $1.5 billion for the previous quarter.The quarter also marks the first set of results under new CEO Meg O'Neill, who is the company’s fourth leader in six years. “Overall, our business continues to run well. This was another quarter of strong operational and financial delivery, and we made further progress towards our 2027 targets,” O’Neill said in a statement.<h2 class="st-heading-2">BP Benefits From Oil Surge</h2>The U.S. and Israel’s war with Iran, which has entered its ninth week, has led to a sharp surge in global oil prices as the critical Strait of Hormuz remains choked amid the conflict.Brent crude futures expiring in June are currently trading at over $111 a barrel at the time of writing, compared with around $72.5 before the war started.BP has also emerged as the <a href="https://stocktwits.com/news-articles/markets/equity/not-batl-chevron-or-exxon-surprise-big-oil-winner-since-us-iran-war/cZBNkanRe2Y">best-performing stock</a> among the top oil supermajors, surging more than 18% since the start of the U.S.-Iran war.<h2 class="st-heading-2">BP Earnings Snapshot</h2>The oil supermajor said that its reported profit for the quarter was $3.8 billion, compared with a loss of $3.4 billion for the fourth quarter of 2025.Meanwhile, the company’s net debt was $25.3 billion at the end of the quarter, up from $22.18 billion as of Dec. 2025. However, BP said that it aims to bring this down to between $14 billion and $18 billion by the end of 2027.BP said it expects lower upstream production in Q2 due to seasonal maintenance and disruptions in the Middle East, while also noting that higher customer volumes may be offset by weaker midstream results. The company also said that its 2026 capital expenditure would be between $13 billion and $13.5 billion.<h2 class="st-heading-2">Retail Stance</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BP">BP stock</a> stayed in the ‘bearish’ territory at the time of writing, amid ‘low’ message volumes.BP stock has gained more than 57% in the last year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of BP plc.

BP Stock Jumps Over 3% Premarket: US-Iran War Drives Best Quarter In Years

BP’s underlying replacement cost profit, which it uses as a proxy for net profit, came in at $3.2 billion for the quarter, compared to $1.5 billion for the previous quarter.

Global Equity ETFs in Focus as AI Optimism Drives Fresh Inflows

AI optimism and easing volatility fuel a $48.7B surge into global equity funds. Here are some global ETFs to consider.

Looking Abroad Again? Global ETFs to Diversify Beyond U.S. Markets

Ceasefire hopes, persistent volatility in the U.S. markets and a softer dollar are driving investors to look beyond domestic equities and toward global equity ETFs for broader diversification.

<ul class="summary-bullets"><li>FDA approved leucovorin in the treatment of cerebral folate transport deficiency last month but not in autism.</li><li>Leucovorin garnered attention in the latter half of 2025 after Donald Trump and his administration promoted it as an "exciting" and “promising” therapeutic for autism.</li><li>According to research published in The Lancet, outpatient leucovorin prescriptions for children aged 5–17 years increased by 71% following the press briefing in September.</li></ul>UK drugmaker GSK Plc (GSK) has withdrawn its application for the drug leucovorin calcium touted by President Trump as a potential treatment for autism.GSK asked the U.S. Food and Drug Administration to pull its application for leucovorin calcium because it no longer markets the medicine, a filing on the FDA website shows.The news was first reported by The Wall Street Journal. &nbsp;<h2 class="st-heading-2">Leucovorin Approval And Claims</h2>According <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/gsk-nixes-application-for-drug-touted-by-trump-for-autism-4d5bdead">to </a>WSJ, GSK said in September that it would submit an application for the drug in the treatment of cerebral folate transport deficiency following a request from the FDA. The agency approved the drug for the condition last month, but not for autism. The company, however, hasn’t sold the drug since 1999, the report noted. &nbsp;A GSK spokesperson reportedly told the newspaper that the company never intended to sell the drug again. Meanwhile, a spokesperson for the U.S. Department of Health and Human Services told the paper that GSK’s decision has no bearing on generic versions of the drug for patients with cerebral folate deficiency.Leucovorin garnered attention in the latter half of 2025 after Donald Trump and his administration promoted it as an "exciting" and “promising” therapeutic for autism. According to <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00243-6/fulltext">research</a> published in The Lancet, outpatient leucovorin prescriptions for children aged 5–17 years increased by 71% following the press briefing in September where Trump made his claims with Robert F Kennedy Jr.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around GSK stock stayed within the ‘bearish’ territory, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/GSK">GSK stock</a> has gained 69% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-heads-for-8th-straight-week-of-price-decline/cZJWlLZRIsZ">TSLA Stock Heads For 8th Straight Week Of Price Decline — What’s Driving The Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Reportedly Pulls Application For Drug Touted By Trump As Potential Treatment For Autism

According to a report from the Wall Street Journal on Thursday, GSK asked the FDA to pull its application for leucovorin calcium because it no longer markets the medicine.

<ul class="summary-bullets"><li>Novo got approval for the higher dose of its Wegovy injection in March based on results from a late-stage clinical trial in which 89% of participants taking the higher dose achieved 5% or greater weight loss at 72 weeks.</li><li>Novo said on Tuesday that self paying adults prescribed Wegovy HD can expect a price of $399/month.</li><li>In January, Novo also launched its weightloss pill, in a bid to regain market share being eroded by rival Eli Lilly and Co.</li></ul>Shares of Novo Nordisk (NVO) saw increased retail chatter on Tuesday after the company announced the availability of its higher dose Wegovy injection across the U.S.On Stocktwits, retail sentiment around NVO stock stayed within the ‘neutral’ territory over the past 24 hours. Retail chatter around the stock jumped 136% over the same time frame.A Stocktwits user said that NVO stock remains “stubbornly undervalued.”<stembedurl>https://www.stocktwits.com/Johnnytwofour2/message/649581803</stembedurl>Another sounded hopes for a big move.<stembedurl>https://www.stocktwits.com/jonztown/message/649554573</stembedurl>The Wegovy HD injection 7.2 mg will be available through over 70,000 U.S. pharmacies, including Novo’s own NovoCare Pharmacy and select telehealth providers, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/novo-nordisks-wegovy-hd-available-now-nationwide-302735677.html">said</a>. The higher dose delivers the highest weight loss of any Wegovy injection to date. &nbsp;<h2 class="st-heading-2">Wegovy HD Approval</h2>Novo got approval for the higher dose of its Wegovy injection in March based on results from a late-stage clinical trial in which 89% of participants taking the higher dose achieved 5% or greater weight loss at 72 weeks as compared to 38% amongst those taking placebo.Prior to its approval, the highest approved dose of Wegovy injectable for weight loss was 2.4 mg.Novo said on Tuesday that self paying adults prescribed Wegovy HD can expect a price of $399/month.“Whether patients haven't yet reached their weight loss goals on lower-dose Wegovy injectables, or they simply have a more significant amount of weight to lose, the 21% weight loss demonstrated in the STEP UP trial, if all patients stayed on treatment, shows what's possible with this new dose, and that's an opportunity we're excited to provide," said Ed Cinca, senior vice president, Marketing and Patient Solutions at Novo Nordisk.<h2 class="st-heading-2">Novo Outlook</h2>In January, Novo also launched its weightloss pill, in a bid to regain market share being eroded by rival Eli Lilly and Co (LLY).However, the company now expects its adjusted sales growth for 2026 to be down 5% to 13% at constant exchange rates, owing to lower realised prices and competition, among other factors.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 42% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/hyperscale-data-reports-nearly-double-its-market-cap-in-assets/cZJJwKlRIpM">Hyperscale Data Reports $102 Million In Assets, Nearly Double Its Market Cap</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Launches Higher Dose Of Wegovy Injection Across US — Retail Thinks Stock Is ‘Terribly Undervalued’

The Wegovy HD injection 7.2 mg will be available through over 70,000 U.S. pharmacies including Novo’s own NovoCare Pharmacy and select telehealth providers, the company said.

<ul class="summary-bullets"><li>Analysts at BofA nearly doubled their price target for HIMS stock following the company’s deal with Novo.</li><li>The firm now has a price target of $23, up from $12.5, while the rating has been upgraded to ‘Neutral’ from ‘Underperform’.</li><li>The firm stated that Novo dropping its patent infringement lawsuit against Hims is a “clear positive” for the telehealth operator.</li></ul>Novo Nordisk AS’s (NVO) deal with Hims &amp; Hers Health Inc. (HIMS) has turned Wall Street bullish on both companies, with analysts stating that it helps them in dealing with a commercial headwind and removes a litigation risk from the equation.According to TheFly, analysts at BMO Capital noted that the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk">Novo Nordisk-Hims deal</a> to sell branded GLP-1 is a significant step forward in helping the Ozempic maker address a commercial headwind.The firm maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were down about 1% in Tuesday’s pre-market trade, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers shares</a> were up nearly 5% at the time of writing. Retail sentiment around HIMS stock trended in the ‘extremely bullish’ territory on the platform.<h2 class="st-heading-2">Why Are Analysts Bullish On HIMS?</h2>Analysts at BofA nearly doubled their price target for HIMS stock following the company’s deal with Novo. The firm now has a price target of $23, up from $12.5, while the rating has been upgraded to ‘Neutral’ from ‘Underperform’.The firm stated that Novo dropping its patent infringement lawsuit against Hims is a “clear positive” for the telehealth operator. BofA sees the risk-to-reward ratio as balanced now following the deal.Deutsche Bank also hiked its price target for HIMS to $28 from $25, implying an upside of more than 26% from Monday’s closing price. The firm cited the Novo deal for its price target hike, while keeping a ‘Hold’ rating on the HIMS stock.<h2 class="st-heading-2">What Did Novo, Hims Agree On?</h2>Hims and Novo Nordisk announced a partnership to offer Ozempic and Wegovy at affordable self-pay prices on the telehealth company’s platform.Hims &amp; Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. The company stated that Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg are covered. It will also include Wegovy injections in 1.7 mg and 2.4 mg doses, while Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are covered.It added that these Ozempic and Wegovy offerings will be made available on its platform later this month.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One bullish user on Stocktwits believes selling HIMS stock at this point will be one of the “biggest mistakes” of their life.&nbsp;<stembedurl>https://stocktwits.com/TradeOrGoHome/message/647084706</stembedurl>Another user stated that every dip in the NVO stock is a “gift.”<stembedurl>https://stocktwits.com/King_of_the_bagholders/message/647086431</stembedurl><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 22% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 32%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iran-war-hegseth-most-intense-day-of-strikes-iranian-leaders-scrambling/cZdoAnzRI75">Iran War: Defense Secretary Hegseth Warns Of ‘Most Intense’ Strikes, Says The Middle East Country Is ‘Badly Losing’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

<ul class="summary-bullets"><li>Hims &amp; Hers said that existing patients will have the opportunity to transition to FDA-approved medicines when their providers deem it clinically appropriate.</li><li>The company stated that Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg are covered.</li><li>It will also include Wegovy injections in 1.7 mg and 2.4 mg doses, while Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are also covered.</li></ul>Shares of Hims &amp; Hers Health Inc. (HIMS) surged more than 52% in Monday’s pre-market trading after Novo Nordisk A/S (NVO) partnered with the telehealth platform to offer Ozempic as well as Wegovy at affordable self-pay prices and dropped its patent infringement lawsuit against the company.Hims &amp; Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. Existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate by their providers, the company said.<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were up more than 2% in Monday’s opening trade, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers shares</a> were up around 39% at the time of writing. Retail sentiment around HIMS stock trended in the ‘extremely bullish’ territory on the platform.<h2 class="st-heading-2">What Does The Agreement Include?</h2>Hims &amp; Hers stated that the Ozempic and Wegovy offerings will be made available on its platform later this month.This includes Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg and will also include Wegovy injections in doses of 1.7 mg and 2.4 mg. Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are also covered.Over the coming months, Hims &amp; Hers will educate U.S. weight loss customers about their options across a wider range of FDA-approved treatments. When providers determine it is clinically appropriate, the company will help support a smooth transition to these medications, the company said.<h2 class="st-heading-2">Novo’s Allegations</h2>In&nbsp;February this year, Novo had sued Hims &amp; Hers,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2">stating</a> that the latter is duping consumers and healthcare professionals about the clinical benefits and safety of these unapproved drugs.The U.S. Food and Drug Administration (FDA) also warned of a crackdown last week on GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs.“These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy.&nbsp; We take seriously any potential violations of the Federal Food, Drug, and Cosmetic Act,” the agency said.Subsequently, Hims &amp; Hers announced that it would stop offering the $49 compounded version of Novo’s Wegovy.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 23% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 33%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-declines-immunitybio-resubmits-anktiva-application-to-fda/cZdVj9URIIL">ImmunityBio Resubmits Supplemental Biologics License Application To FDA For Ankitva — IBRX Stock Declines Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Hims & Hers Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.

<ul class="summary-bullets"><li>Novo Nordisk stated that its price cuts for Ozempic and Wegovy are intended to benefit insured patients.</li><li>The company said this will also benefit patients who pay out of pocket, but their costs are tied to the list price of these drugs.</li><li>Novo Nordisk said this applies to patients with high-deductible health plans or co-insurance benefit designs.</li></ul>Novo Nordisk AS (NVO) is planning to cut Ozempic and Wegovy prices in the U.S. by up to 50% starting in 2027.Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company. This is a 50% reduction when compared to the current list price of Wegovy, and about 35% cut for the list price of Ozempic.“Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States,” said Jamey Millar, Novo Nordisk’s Executive Vice President of U.S. operations.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk shares</a> were down nearly 2% in Tuesday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Who Will Benefit From These Lower Prices?</h2>Novo Nordisk stated that its price cuts for Ozempic and Wegovy are intended to benefit insured patients.This will also benefit patients who pay out of pocket, but whose costs are linked to the list price of these drugs. This applies to patients with high-deductible health plans or co-insurance benefit designs, the company said.Novo Nordisk added that Tuesday’s price cuts do not impact its direct-to-consumer and self-pay offerings of Ozempic and Wegovy.<h2 class="st-heading-2">Ozempic And Wegovy Prices For Cash-Paying Patients</h2>Novo Nordisk currently offers Wegovy for cash-paying patients, starting at $149 per month for the pill and $199 per month for the pen.Ozempic prices start at $199 a month for the first two months for new patients for 0.25 mg and 0.5 mg doses.Existing patients can get Ozempic in 0.25 mg, 0.5 mg, and 1 mg doses at $349 per month.All patients will have to pay $499 a month for the 2 mg dose of Ozempic.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 24% year-to-date and 56% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-stock-soars-on-meta-expanded-6-gigawatt-deal-for-amd-gpus/cZRvDZZR4Cb">AMD Stock Soars Pre-Market After Meta Expands Multi-Year AI Chip Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Still life of Novo Nordisk's Wegovy semaglutide tablets with injectable prescription weight loss medicines, Ozempic, and Wegovy

Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%

Ozempic and Wegovy will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company.

AVDE
American Century ETF Trust - Avantis International Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest AVDE News

AVDEAmerican Century ETF Trust - Avantis International Equity ETF